(Q35233621)

English

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. (English)

1 reference

Europe PubMed Central

7 August 2017

author name string

William P Kennedy

1

1 reference

Europe PubMed Central

7 August 2017

Romeo Maciuca

2

1 reference

Europe PubMed Central

7 August 2017

Kristen Wolslegel

3

1 reference

Europe PubMed Central

7 August 2017

Wei Tew

4

1 reference

Europe PubMed Central

7 August 2017

Alexander R Abbas

5

1 reference

Europe PubMed Central

7 August 2017

Christina Chaivorapol

6

1 reference

Europe PubMed Central

7 August 2017

Alyssa Morimoto

7

1 reference

Europe PubMed Central

7 August 2017

Jacqueline M McBride

8

1 reference

Europe PubMed Central

7 August 2017

Paul Brunetta

9

1 reference

Europe PubMed Central

7 August 2017

Bruce C Richardson

10

1 reference

Europe PubMed Central

7 August 2017

John C Davis

11

1 reference

Europe PubMed Central

7 August 2017

Timothy W Behrens

12

1 reference

Europe PubMed Central

7 August 2017

Michael J Townsend

13

1 reference

Europe PubMed Central

7 August 2017

publication date

28 March 2015

1 reference

Europe PubMed Central

7 August 2017

Lupus science & medicine

1 reference

Europe PubMed Central

7 August 2017

2

1 reference

Europe PubMed Central

7 August 2017

1

1 reference

Europe PubMed Central

7 August 2017

e000080

1 reference

Europe PubMed Central

7 August 2017

Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

The interferon signature in autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

The genetics of type I interferon in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

The JAK-STAT pathway at twenty

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Measuring outcomes in systemic lupus erythematosus clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Type I interferon in organ-targeted autoimmune and inflammatory diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Independent filtering increases detection power for high-throughput experiments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Innate immunity to virus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Complement deficiencies and systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Type I interferon in systemic lupus erythematosus and other autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

The type I interferon system in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

Systemic lupus erythematosus: prototype of immune complex nephritis in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

13 July 2018

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

26 September 2018

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

26 September 2018

Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379884

26 September 2018

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/25861459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25861459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/LUPUS-2014-000080

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35233621&oldid=1616149499"